CTOs on the Move

CereVasc

www.cerevasc.com

 
The CereVasc eShunt™ device is intended to improve patient outcomes and redefine the treatment of communicating hydrocephalus.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.cerevasc.com
  • 2120 Commonwealth Avenue Suite 1
    Auburndale, MA USA 02466
  • Phone: N/A

Executives

Name Title Contact Details

Funding

CereVasc raised $44M on 06/09/2020

Similar Companies

Alaunos

Alaunos is a clinical stage cellular immuno-oncology company dedicated to the treatment of solid tumors through adoptive TCR-T cell therapy. With our robust and innovative discovery engine, we strike cancer at its core by engineering cell therapies that target neoantigens arising from genomic mutations. We have developed proprietary, rapid, cost-effective solutions to deliver tumor-specific killer T cells to large cancer patient populations with unmet clinical need. We are based in Houston, TX, home to the largest medical center in the world; and in a state with no state income tax and a low cost of living. For more information about Alaunos, please visit www.alaunos.com. Click on the Careers tab of our web page to join our exciting team and help make a difference in the lives of cancer patients and their families.

Bolt Biotherapeutics

Bolt Biotherapeutics is a start-up with compelling technology from Dr. Engleman`s Lab at Stanford University, which demonstrated complete cures in numerous cancer models.

Willow Industries

Willow Industries Ozone Systems. Mitigate Mold & Bacteria. Willow systems provide clean and effective solutions to cannabis contamination.

F1 Oncology

We are harnessing the power of the immune system to target some of the most challenging solid tumor malignancies.

Fulcrum Therapeutics

Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum`s proprietary product engine, FulcrumSeek™, identifies drug targets which can modulate gene expression to treat the known root cause of gene mis-expression. The company has advanced losmapimod to Phase 2 clinical development for the treatment of facioscapulohumeral muscular dystrophy (FSHD). Fulcrum has also advanced FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and beta-thalassemia into Phase 1 clinical development.